Nonalcoholic Steatohepatitis Treatment Market Gets No Buzz

  • The primary mechanisms of nonalcoholic steatohepatitis are obesity, glucose intolerance, metabolic stress, inflammation, dyslipidemia and fibrosis.
  • Nonalcoholic steatohepatitis can develop into cirrhosis and liver cancer.
  • For the diagnosis of the nonalcoholic steatohepatitis, liver biopsy, imaging procedures and various types of blood tests including complete blood count, fasting blood sugar, liver enzyme tests etc.

Nonalcoholic steatohepatitis is a syndrome which causes liver damage that develops in individuals who are not alcoholic. The primary mechanisms of nonalcoholic steatohepatitis are obesity, glucose intolerance, metabolic stress, inflammation, dyslipidemia and fibrosis.

Nonalcoholic steatohepatitis can develop into cirrhosis and liver cancer. For the diagnosis of the nonalcoholic steatohepatitis, a liver biopsy, imaging procedures and various types of blood tests including complete blood count, fasting blood sugar, liver enzyme tests etc. are required. The common nonalcoholic steatohepatitis treatment may include weight loss, type-2 diabetes treatment, a decrease of obesity etc. However, of the many drugs which have been tested for nonalcoholic steatohepatitis treatment, only a few drugs such as vitamin E and pioglitazone showed a positive effect.

To Understand How Our Report Information Can Bring Difference, Ask for a brochure

For the diagnosis of the nonalcoholic steatohepatitis, liver biopsy, imaging procedures and various types of blood tests including complete blood count, fasting blood sugar, liver enzyme tests etc.

Other drugs such as ursodeoxycholic acid, metformin, statins, orlistat and pentoxifylline showed only partially positive results. In the last several years nonalcoholic steatohepatitis is continuously increasing in both developed and emerging countries. According to the “National Health and Nutrition Examination Survey,” the proportion of Nonalcoholic fatty liver disease among chronic liver diseases increased from 47% to 75% between 1988 and 2008 in the United States (US).

Major elements that can be considered for the pathological protagonists of nonalcoholic steatohepatitis are oxidative stress, altered lipid metabolism adipose and pancreas tissues, bile acids, gut microbiota, bacterial endotoxins, and systemic chronic inflammation. However, more clinical studies and drug approvals by regulatory authorities are  essential for nonalcoholic steatohepatitis treatment during forecast periods.

The nonalcoholic steatohepatitis treatment market can be segmented by drug types, test types and end-user. Based on the drug types the nonalcoholic steatohepatitis treatment market can be segmented as Vitamin E Supplement, Pioglitazone, Ursodeoxycholic Acid, Metformin, Statins, Pentoxifylline and Orlistat.

Based on the test types the nonalcoholic steatohepatitis treatment market can be segmented as Blood Tests, Complete Blood Count, Fasting Blood Sugar, Liver Enzyme And Liver Function Tests, Celiac Disease Screening Test, Tests For Chronic Viral Hepatitis (Hepatitis A, Hepatitis C And Others), Lipid Profile, Which Measures Blood Fats, Such As Cholesterol And Triglycerides, Hemoglobin A1c (Which Shows How Stable Your Blood Sugar Is). Imaging Procedures, Abdominal Ultrasound, Magnetic Resonance Imaging (MRI), Computerized Tomography (CT) Scanning, Magnetic Resonance Elastography, Transient Elastography, and Liver Biopsy.

Based on the end-user the nonalcoholic steatohepatitis treatment market can be segmented as Hospitals, Diagnostic Centers, Specialized Clinics, Home Care Settings, Hospital Pharmacy, Drug Stores, and Mail Order Pharmacy.

Request PMR insights on measuring the impact of COVID-19 coronavirus across industries

Increasing incidents of obesity due to unhealthy diets and weight gain promotes nonalcoholic

Of the many drugs which have been tested for nonalcoholic steatohepatitis treatment, only a few drugs such as vitamin E and pioglitazone showed a positive effect.

steatohepatitis syndrome which drives the nonalcoholic steatohepatitis treatment market. Increasing prevalence of type 2 diabetes, obesity and dyslipidemia lead to nonalcoholic steatohepatitis disease, which drives the nonalcoholic steatohepatitis treatment market. However, because there are so few Food and Drug Administration (FDA) approved drugs for nonalcoholic steatohepatitis treatment, growth of the nonalcoholic steatohepatitis treatment market is restrained.

North America is expected to have the largest regional market share in the nonalcoholic steatohepatitis treatment market due to the presence of more market players, increasing awareness about nonalcoholic steatohepatitis treatment and marketing activities in the region followed by Europe. The nonalcoholic steatohepatitis treatment market is expected to grow fastest in the Asia Pacific may because of the increasing prevalence of obesity, high cholesterol and type-2 diabetes, thus boosting market growth. However, in the South Asian countries such as India and China, the opportunities to manufacture and distribute new nonalcoholic steatohepatitis treatment drugs is expected to be higher due to large populations and increasing incidence of type-2 diabetes and obesity during forecasting periods.

Some of the Key Market Players operating in the nonalcoholic steatohepatitis treatment market are Allergan Inc., Galmed Pharmaceuticals Ltd., GENFIT, Gilead Sciences Inc., Intercept Pharmaceuticals, Zydus and Cadila among others.

To Gain More Insights & Stay Ahead Of The Competition, Buy Now

Only $1/click

Submit Your Ad Here

Swapna Supekar

Swapna work as a Sr. Digital Marketing Consultant with Persistence Market Research. 
https://www.persistencemarketresearch.com

Leave a Reply